Literature DB >> 1675867

A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure.

M J Jamieson1, J Webster, G Fowler, J Rawles, F W Smith, J C Petrie.   

Abstract

1. We compared the effects, after 3 weeks oral therapy, of xamoterol 200 mg twice daily and enalapril 2.5, 5 or 10 mg twice daily on home and clinic blood pressure, glomerular filtration rate (GFR) and renal plasma flow, stroke and minute distances, linear resistance and on plasma renin activity in 19 patients with mild to moderate heart failure in a single-blind randomised crossover study. 2. Enalapril reduced mean home blood pressure by 17/7 mm Hg compared with xamoterol (P less than 0.0001) and by 19/7 mm Hg compared with placebo. Compared with placebo xamoterol had no effect. Enalapril reduced predose blood pressure, compared with xamoterol, on average by 15/5 mm Hg (P = 0.02 systolic, 0.09 diastolic) and by 20/7 mm Hg compared with placebo. At 4 h post-dose the mean differences were: xamoterol-enalapril 13/10 mm Hg (P = 0.01 systolic, 0.0007 diastolic) and placebo-enalapril 23/9 mm Hg. 3. Stroke and minute distances were marginally less 4 h following xamoterol than following enalapril: mean (s.e. mean) values were 9.4 (0.7) vs 10.4 (0.8) cm (P = 0.23) and 699 (51.7) vs 767 (62.1) cm (P = 0.04) respectively. Linear resistance was reduced by enalapril, from the placebo value of 13.2 (1.2) to 11.0 (0.9) mm Hg m-1 and marginally increased by xamoterol, to 14.2 (1.2) mm Hg m-1, the difference between active treatments being statistically significant (P = 0.03). 4. Renal plasma flow, GFR and filtration fraction were not influenced by enalapril or xamoterol therapy. There were no significant correlations between glomerular filtration rate and either blood pressure or stroke distance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675867      PMCID: PMC1368357          DOI: 10.1111/j.1365-2125.1991.tb05534.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Haemoglobin concentration and linear cardiac output, peripheral resistance, and oxygen transport.

Authors:  M K Daniel; B Bennett; A A Dawson; J M Rawles
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

2.  Effects of xamoterol on sodium excretion in volunteers.

Authors:  P Y Zech; N Pozet; M A Day; H M Snow; O Madonna; A Hadj-Aissa
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure.

Authors:  M A Creager; J L Halperin; D B Bernard; D P Faxon; C D Melidossian; H Gavras; T J Ryan
Journal:  Circulation       Date:  1981-09       Impact factor: 29.690

4.  Effect of captopril on renal function in patients with congestive heart failure.

Authors:  G L Pierpont; G S Francis; J N Cohn
Journal:  Br Heart J       Date:  1981-11

5.  Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.

Authors:  M Packer; W H Lee; N Medina; M Yushak; P D Kessler
Journal:  Ann Intern Med       Date:  1987-03       Impact factor: 25.391

6.  Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system.

Authors:  M Packer; W H Lee; P D Kessler
Journal:  Circulation       Date:  1986-10       Impact factor: 29.690

7.  Benefits and potential harm of lowering high blood pressure.

Authors:  J M Cruickshank; J M Thorp; F J Zacharias
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

8.  Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.

Authors:  V J Dzau; W S Colucci; G H Williams; G Curfman; L Meggs; N K Hollenberg
Journal:  N Engl J Med       Date:  1980-06-19       Impact factor: 91.245

9.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Authors:  J G Cleland; H J Dargie; S G Ball; G Gillen; G P Hodsman; J J Morton; B W East; I Robertson; I Ford; J I Robertson
Journal:  Br Heart J       Date:  1985-09

10.  The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure.

Authors:  E R Powers; K S Bannerman; J Stone; D S Reison; E L Escala; A Kalischer; M B Weiss; R R Sciacca; P J Cannon
Journal:  Am Heart J       Date:  1982-11       Impact factor: 4.749

View more
  3 in total

1.  Renal effects of xamoterol in patients with moderate heart failure.

Authors:  H E Bøtker; H K Jensen; L R Krusell; E V Sørensen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

2.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2021-05-22

Review 3.  Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.

Authors:  Nicole Martin; Karthick Manoharan; James Thomas; Ceri Davies; R Thomas Lumbers
Journal:  Cochrane Database Syst Rev       Date:  2018-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.